This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Valkonen, V.-P. Articles by Laaksonen, R. Search for Related Content PubMed PubMed Citation Articles by Valkonen, V.-P. Articles by Laaksonen, R. Social Bookmarking                         What's this?

DDAH gene and cardiovascular risk

The Research Institute of Public Health, University of Kuopio, Kuopio, Finland

Tomi-Pekka Tuomainen

The Research Institute of Public Health, University of Kuopio, Kuopio, Finland

Reijo Laaksonen

Viikki Drug Discovery Technology Center, University of Helsinki, Finland

The crucial role of nitric oxide (NO) for normal endothelial function is well known. In many conditions associated with increased risk of cardiovascular diseases such as hypercholesterolemia, hypertension, abdominal obesity, diabetes and smok ing, NO biosynthesis is dysregulated, leading to endothelial dysfunction. The grow ing evidence from animal and human studies indicates that endogenous inhibitors of endothelial NO synthase such as asymmetric dimethylarginine (ADMA) and N^G-monomethyl-L-arginine (L-NMMA) are associated with the endothelial dysfunc tion and potentially regulate NO synthase. The major route of elimination of ADMA is metabolism by the enzymes dimethylarginine dimethylaminohydrolase-1 and -2 (DDAH). In our recent study 16 men with either low or high plasma ADMA concen trations were screened to identify DDAH polymorphisms that could potentially be associated with increased susceptibility to cardiovascular diseases. In that study a novel functional mutation of DDAH-1 was identified; the mutation carriers had a significantly elevated risk for cardiovascular disease and a tendency to develop hypertension. These results confirmed the clinical role of DDAH enzymes in ADMA metabolism. Furthermore, it is possible that more common variants of DDAH genes contribute more widely to increased cardiovascular risk.

Key Words: ADMA • DDAH • cardiovascular disease • gene mutation

Vascular Medicine, Vol. 10, No. 1 suppl, S45-S48 (2005)
DOI: 10.1177/1358836X0501000107


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?